Vice President, Vaccine Development
Thomas Hassell leads IAVI’s efforts to rapidly advance the most promising HIV vaccine candidates from the laboratory into clinical trials, accelerating the product development process.
Hassell has more than 30 years of industry experience with several leading vaccine developers and has led efforts to take early stage vaccine candidates for several major diseases from ideas, all the way through to licensure. Prior to joining IAVI, he led a team of researchers as global vice president of process development at Sanofi Pasteur. His teams successfully spearheaded international licensure of Pentacel — a childhood combination vaccine against diphtheria, tetanus, whooping cough, Haemophilus Influenzae Type B, and polio — as well as Menactra, the first conjugate vaccine to provide protection against four strains of bacterial meningitis.
He holds a Ph.D. in microbiology from Manchester Metropolitan University in the U.K., and completed a postdoctoral program at the Massachusetts Institute of Technology as a Rockefeller Foundation Fellow.